Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma

The purpose of this research is to determine if additional imaging during radiotherapy allows for better understanding of tumor's response to radiation and better treatment planning. Modern cancer treatment has used imaging to tailor individual patient treatment and to monitor responses to therapy. Typically, assessments of tumor response to radiation are conducted by repeat imaging after completing therapy. It is known that radiation can change aspects of the tumor which impact response to therapy. These changes can potentially be seen in imaging of the tumor. The researchers in this study believe that additional imaging during treatment will allow for more personalized and better treatment for sarcoma.

Inclusion criteria

• Patients must have histologically or cytologically confirmed history of soft tissue sarcoma.
• Plan to receive neoadjuvant radiation to a dose of 50 Gy in 25 fractions followed by surgical resection per Investigator.
• Age ≥18 years.
• ECOG performance status ≤2.

Exclusion criteria

• Patients with Ewing's sarcoma and rhabdomyosarcoma.
• Unable or unwilling to receive gadolinium-based contrast.
• Patients who are unable or unwilling to undergo MRI studies.
• Patients who may be unlikely or unable to be able to complete 3 additional MRI studies during the course of their 5-week radiation plan in the opinion of the PI.